Moderna, Inc. (MRNA) vs Royalty Pharma PLC (RPRX)
- Moderna, Inc. MRNA 218.01 −7.82%
- Royalty Pharma PLC RPRX 61.29 +2.80%
Moderna, Inc. and Royalty Pharma PLC are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $94.4B against $34.3B — 2.8× the size. Moderna, Inc. has negative trailing earnings, so its P/E is not meaningful; Royalty Pharma PLC trades at 42.3×. Royalty Pharma PLC grew revenue faster over the last twelve months: 10.0% against −27.6%. Royalty Pharma PLC has the higher net margin (32.0% vs −141.4%) and the higher return on invested capital (5.28% vs −93.5%). Across the 19 metrics below, Royalty Pharma PLC leads on 14 and Moderna, Inc. on 5.
Valuation
Profitability
| Metric | MRNA | RPRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 23.38% | 100.00% | 65.16% |
| Operating margin | (149.01%) | 59.61% | 0.00% |
| Net margin | (141.43%) | 32.02% | 0.00% |
| Free cash flow margin | (55.83%) | 51.66% | 0.00% |
| Return on equity | (39.00%) | 8.42% | (56.36%) |
| Return on assets | (27.43%) | 4.26% | (48.04%) |
| Return on invested capital | (93.47%) | 5.28% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack